Who we are

Pelago Bioscience was founded in 2013 with the aim to develop the patented Cellular Thermal Shift Assay (CETSA®) for maximum utility and customer value in drug discovery and diagnostics. The company delivers in situ target engagement studies to accelerate preclinical and clinical drug discovery and diagnostics development. Using CETSA data and applications, drug discovery R&D companies are able to make better and more informed decisions at earlier stages in their projects. Our scientific team are the experts in both targeted (Classics & HT) and unbiased proteomics (Mass Spectrometry) CETSA applications, find out more under our services page.

Our state-of-the-art laboratories are based in Stockholm, a city formed from a collection of islands called the Archipelago.

Our Leadership Team

Michael Dabrowski

Michael Dabrowski

CEO

Daniel Martinez Molina

Daniel Martinez Molina

CSO

Catrine Siöberg

Catrine Siöberg

VP Operations

Sean Tyacke

Sean Tyacke

VP, Sales & Marketing